Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Top Cited Papers
- 15 December 2002
- journal article
- clinical trial
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 63 (12) , 1140-1147
- https://doi.org/10.4088/jcp.v63n1209
Abstract
Atomoxetine is a nonstimulant drug being studied for the treatment of attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a highly specific inhibitor of the presynaptic norepinephrine transporter with minimal affinity for other noradrenergic receptors or other neurotransmitter transporters or receptors. Results of 2 proof-of-concept studies are reported that tested the hypothesis that a selective inhibitor of presynaptic norepinephrine uptake would be effective for the treatment of ADHD in school-aged children.Keywords
This publication has 0 references indexed in Scilit: